Journals / Türkderm-Deri Hastalıkları ve Frengi Arşivi / 2004 / Cilt: 38 - Sayı: 3

Evaluation of anticardiolipin anticores and tendency of thrombosis in cutaneous vasculitis

Kutanöz vaskülitte antikardiolipin antikorlar ve tromboz eğiliminin araştırılması

Pages
185–190
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: It was concluded that cutaneous vasculitis carries no risk of thrombosis and ACA positivity in the absence of systemic involvement.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Endothelial cell activation and inflammation in the vessel wall along with anticardiolipin anticores (ACA) were reported to facilitate thrombus formation in vasculitis.
📊
Key Findings & Data:Materials and methods: Eighteen patients diagnosed as cutaneous leukocytoclastic vasculitis with clinical and laboratory findings and 18 healthy controls were enrolled in the study.
💡
Conclusion & Impact:Conclusion: It was concluded that cutaneous vasculitis carries no risk of thrombosis and ACA positivity in the absence of systemic involvement.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: Endothelial cell activation and inflammation in the vessel wall along with anticardiolipin anticores (ACA) were reported to facilitate thrombus formation in vasculitis. This is important in means of the pathogenesis, progression and effective treatment alternatives of the disease. In the present study, it is aimed to reveal the tendency of thrombosis in cutaneous vasculitis with clinical and laboratory investigation. Materials and methods: Eighteen patients diagnosed as cutaneous leukocytoclastic vasculitis with clinical and laboratory findings and 18 healthy controls were enrolled in the study. The etiology of vasculitis was investigated in the patient group as well as serum protein C, protein S, antithrombin III levels, prothrombin and partial thromboplastin time, bleeding and coagulation times. Patient and control groups were compared in means of serum ACA IgM and IgG positivity. Results: Systemic involvement was not observed with clinical and laboratory investigations as well as thrombotic risk factors in the patient group. ACA IgM positivity was not detected in any of the groups while ACA IgG levels were moderately elevated in two patients whereas all of the controls were ACA IgG negative. There was no difference between patient and control groups in means of serum ACA IgG positivity (p=0.486, Fischer’s exact test). Conclusion: It was concluded that cutaneous vasculitis carries no risk of thrombosis and ACA positivity in the absence of systemic involvement.

Özet

Amaç: Vaskülitlerde damar duvarındaki endotel hücre aktivasyonu ve inflamasyon ile birlikte antikardiolipin antikorların (ACA) trombus gelişimini kolaylaştırabileceği bildirilmiştir. Bu durum, vaskülit patogenezi, seyri ve doğru tedavi seçeneklerinin belirlenmesinde önem taşımaktadır. Çalışmamızda kutanöz vaskülitli hastalarda klinik ve laboratuvar açıdan tromboza eğilimin belirlenmesi amaçlanmıştır. Gereç ve Yöntem: Çalışmaya klinik ve histopatolojik bulgularla kutanöz lökositoklastik vaskülit tanısı alan 18 hasta ile 18 sağlıklı kontrol alındı. Hasta grubu vaskülit etyolojisi açısından araştırıldığı gibi serumda protein C, protein S, antitrombin III düzeyleri, protrombin zamanı, parsiyel tromboplastin zamanı, kanama ve pıhtılaşma zamanları değerlendirildi. Hasta ve kontrol grubu serum ACA IgM ve IgG pozitifliği açısından karşılaştırıldı.Bulgular: Hasta grubunda klinik ve laboratuvar bulguları açısından sistemik tutulum varlığına rastlanmazken trombotik risk faktörleri de normal olarak değerlendirildi. ACA IgG, iki olguda orta derecede yüksek olup kontrol grubunda negatif bulunurken ACA IgM olguların tümünde negatif idi. Hasta ve kontrol grubu arasında serum ACA IgG pozitifliği açısından fark saptanmadı (p=0.486, Fischer’in exact testi). Sonuç: Sistemik tutuluma ait bulgu yoksa kutanöz vaskülitin tromboza eğilim ve ACA pozitifliği açısından risk taşımadığı sonucuna varıldı.

🔖

Cite This Article

CAN, R., ADİLOĞLU, A., AKKAYA, V. B., BAŞAK, P. Y., ÖZCANLI, Ç. (2022). Evaluation of anticardiolipin anticores and tendency of thrombosis in cutaneous vasculitis. Türkderm-Deri Hastalıkları ve Frengi Arşivi, Cilt: 38 - Sayı: 3, 185–190. https://ajindex.com/articles/622227

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Jurd KM, Stephens CJM, Black MM, Hunt BJ: Endothelial cell activation in cutaneous vasculitis. Clin Exp Dermatol 1996; 21: 28-32
  2. Soter NA: Cutaneous necrotizing venulitis. In: Fitzpatrick’s dermatology in general medicine. Eds. Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, Fitzpatrick TB. 5’inci Bask›. New York, Mc-Graw-Hill, 1999; 2044-2053
  3. Sais G, Vidaller A, Jucgla A, Servitje O, Condom E, Peyri J: Prognostic factors in leukocytoclastic vasculitis: a clinicopathologic study of 160 patients. Arch Dermatol 1998; 134: 309-315
  4. Burden AD, Tillman DM, Foley P, Holme E: IgA class anticardiolipin antibodies in cutaneous leukocytoclastic vasculitis. J Am Acad Dermatol 1996; 35: 411-415
  5. Wang CR, Liu MF, Tsai RT, Chuang CY, Chen CY: Circulating intercellular adhesion molecules-1 and autoantibodies including anti-endothelial cell, anti-cardiolipin, and anti-neutrophil cytoplasma antibodies in patients with vasculitis. Clin Rheumatol 1993; 12: 375-380
  6. Gibson GE, Su WP, Pittelkow MR: Antiphospholipid syndrome and the skin. J Am Acad Dermatol 1997; 36: 970-982
  7. Gantcheva M, Angelova I: Antiphospholipids in cutaneous vasculitis. Clin Dermatol 1999; 17: 619-624
  8. İnanır I, Aktan Ş: Antifosfolipid Sendromu. Türkderm 1999; 33: 262-265
  9. Sais G, Vidaller A, Peyri J: Anticardiolipin antibodies in leukocytoclastic vasculitis. J Am Acad Dermatol 1997; 37: 805-806
  10. Goldberger E, Elder RC, Schwartz RA, Phillips PE:Vasculitis in the antiphospholipid syndrome. A cause of ischemia responding to corticosteroids. Arthritis Rheum 1992; 35: 569-572
  11. Grob JJ, Bonerandi JJ: Thrombotic skin disease as a marker of the anticardiolipin syndrome. Livedo vasculitis and distal gangrene associated with abnormal serum antiphospholipid activity. J Am Acad Dermatol 1989; 20: 1063-1069
  12. Sun NC, Conn DL, Schroeter AL, Kazmier FJ: Skin fibrinolytic activity in cutaneous and systemic vasculitis. Mayo Clin Proc 1976; 51: 216-222
  13. Tomizawa K, Sato-Matsumura KC, Kajii N: The coexistence of cutaneous vasculitis and thrombosis in childhoodonset systemic lupus erythematosus with antiphospholipid antibodies. Br J Dermatol 2003; 149:439-441
  14. Tebbe B, Orfanos CE: Anticardiolipin antibodies in cutaneous lupus erythematosus. Incidence and importance as a marker of vascular symptoms. Hautarzt 1992; 43:130-133
  15. Kabasakal Y: Romatizmal hastalıklarda immünolojik testler. Klinik romatoloji. Ankara, 1996; 66-73
  16. Doğanavşargil E: Sistemik va